{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:54:46Z","timestamp":1761843286466},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1016\/j.ygyno.2004.05.004","type":"journal-article","created":{"date-parts":[[2004,7,30]],"date-time":"2004-07-30T01:36:44Z","timestamp":1091151404000},"page":"404-408","source":"Crossref","is-referenced-by-count":21,"title":["Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum"],"prefix":"10.1016","volume":"94","author":[{"given":"Maurie","family":"Markman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Webster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine","family":"Zanotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gertrude","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Kulp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Belinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2004.05.004_BIB1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2004.05.004_BIB2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0889-8588(03)00058-3","article-title":"Optimizing primary chemotherapy in ovarian cancer","volume":"17","author":"Markman","year":"2003","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.ygyno.2004.05.004_BIB3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1006\/gyno.1993.1252","article-title":"Clinical reversal of drug resistance in ovarian cancer","volume":"51","author":"Ozols","year":"1993","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.004_BIB4","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/cncr.2820710424","article-title":"Mechanisms and modulation of resistance to chemotherapy in ovarian cancer","volume":"71","author":"Perez","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2004.05.004_BIB5","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1200\/JCO.1987.5.4.641","article-title":"Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients","volume":"5","author":"Ozols","year":"1987","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.004_BIB6","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/bjc.1991.484","article-title":"Phase I and pharmacokinetic study of d-verapamil and doxorubicin","volume":"64","author":"Bissett","year":"1991","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2004.05.004_BIB7","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/0006-2952(96)00456-X","article-title":"Sensitization to doxorubicin resistance in breast cancer cell lines by tamoxifen and megestrol acetate","volume":"52","author":"Panasci","year":"1996","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ygyno.2004.05.004_BIB8","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/ijc.2910550623","article-title":"Tamoxifen modulation of cisplatin cytotoxicity in human malignancies","volume":"55","author":"McClay","year":"1993","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2004.05.004_BIB9","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/1097-0142(19900301)65:5<1055::AID-CNCR2820650502>3.0.CO;2-9","article-title":"The effects of estrogen, progesterone, and tamoxifen alone and in combination with cytotoxic agents against human ovarian carcinoma in vitro","volume":"65","author":"Geisinger","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2004.05.004_BIB10","first-page":"6790","article-title":"Modulation of cisplatin resistance in human malignant melanoma cells","volume":"52","author":"McClay","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2004.05.004_BIB11","first-page":"1571","article-title":"Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells","volume":"53","author":"McClay","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2004.05.004_BIB12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/bjc.1994.326","article-title":"Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines","volume":"70","author":"McClay","year":"1994","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2004.05.004_BIB13","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1525-1438.2001.01059.x","article-title":"A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a phase II study","volume":"11","author":"Benedetti Panici","year":"2001","journal-title":"Int. J. Gynaecol. Cancer"},{"key":"10.1016\/j.ygyno.2004.05.004_BIB14","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2002.09.130","article-title":"Phase II trial of weekly single-agent paclitaxel in platinum\/paclitaxel-refractory ovarian cancer","volume":"20","author":"Markman","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.004_BIB15","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0090-8258(03)00399-8","article-title":"Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer","volume":"90","author":"Markman","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.004_BIB16","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.1999.17.2.501","article-title":"Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel","volume":"17","author":"Bridgewater","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.004_BIB17","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1994.12.9.1748","article-title":"Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study","volume":"12","author":"Thigpen","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.004_BIB18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s004320050177","article-title":"Evidence that a \u201ctreatment-free interval of less than 6 months\u201d does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma","volume":"124","author":"Markman","year":"1998","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.004_BIB19","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1200\/JCO.1993.11.10.1957","article-title":"Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program","volume":"11","author":"Ahlgren","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.004_BIB20","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1046\/j.1525-1438.1997.00463.x","article-title":"Tamoxifen in the treatment of recurrent ovarian carcinoma","volume":"7","author":"Marth","year":"1997","journal-title":"Int. J. Gynaecol. Cancer"},{"key":"10.1016\/j.ygyno.2004.05.004_BIB21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1006\/gyno.1996.0181","article-title":"Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group ancillary report","volume":"62","author":"Markman","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2004.05.004_BIB22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/gyno.2001.6489","article-title":"Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research","volume":"84","author":"Perez-Gracia","year":"2002","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825804003142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825804003142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T04:24:22Z","timestamp":1549340662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825804003142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S0090825804003142"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2004.05.004","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}